pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›calendar
  3. ›phase readout
phase readout
save

NCT07281547: Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain

NOT_YET_RECRUITINGupdated 5mo ago
community read0 votes

Sponsor: Mayo Clinic. Phase: PHASE4. Conditions: Endometrial Carcinoma

view source ↗
Data sources
ctgov
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

same company · ±60 days · 6

  • phase 2 completionkava: Mayo Clinic — kava (Phase II Trial Completion)Apr 30, 2026
  • phase 1 2 initiationeflornithine hydrochloride: Mayo Clinic — eflornithine hydrochloride (Phase I/II Trial Initiation)Apr 24, 2026
  • grantMAYO CLINIC ROCHESTER — Establishing the etiology of chronic placental villitis of unknown etiologyApr 1, 2026
  • grantMAYO CLINIC ROCHESTER — Molecular mechanisms of sexually dimorphic traits of interstitial cells of Ca...Apr 1, 2026
  • grantMAYO CLINIC ROCHESTER — Overcoming Challenging Clinical Scenarios in Non-invasive Coronary Artery Ima...Apr 1, 2026
  • grantMAYO CLINIC ROCHESTER — The Lymphoma Epidemiology of Outcomes (LEO) Cohort StudyApr 1, 2026

related news · 8

  • fiercebiotechMayo Clinic teams with Thermo Fisher to form biomedical data group Precure↗
  • biospaceCapricor, Replimune illustrate why FDA must listen to rare disease specialists↗
  • fiercebiotechMeet Aletta: The first FDA approved robotic blood draw device↗
  • statOpinion: How to disrupt the health misinformation business model↗
  • fiercebiotechReplimune’s twice-rejected melanoma drug prevails in FDA adcomm↗
  • statSTAT+: The whistleblower, The Lab, and the fine print↗
  • biopharma diveKardigan extends biotech’s streak of big IPOs with $400M haul↗
  • statHow AI helped treat a newborn’s ultra rare disease. ‘It was almost like a light switch.’↗

🐶 often sniffed alongside

top 8
  • tagOncology7 co-mentions · 6 sources
  • tagGlioblastoma4 co-mentions · 1 sources
  • tagEndocrinology & Metabolism4 co-mentions · 4 sources
  • tagImmunology3 co-mentions · 3 sources
  • tagPain2 co-mentions · 2 sources
  • tagHematology1 co-mentions · 1 sources
  • tagNephrology1 co-mentions · 1 sources
  • tagCardiology1 co-mentions · 1 sources

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?